| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Aalborg Hospital, Aalborg; Department of Neurology, Aarhus University Hospital, Aarhus; and Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark.
Address correspondence and reprint requests to Dr. Troels Staehelin Jensen, Department of Neurology and Danish Pain Research Center, Aarhus University Hospital, 9000 Aarhus, Denmark; e-mail: tsj{at}panter.soci.aau.dk
OBJECTIVE: Central poststroke pain (CPSP) is usually difficult to treat. Amitriptyline, the only oral preparation shown to be effective in a randomized controlled trial, is often associated with a range of side effects related to the many mechanisms of actions of tricyclic antidepressants. We investigated the effect of lamotrigine, a drug that reduces neuronal hyperexcitability, on poststroke pain.
METHODS: Thirty consecutive patients with CPSP (median age 59 years, range 37 to 77; median pain duration 2.0 years, range 0.3 to 12) from two centers participated in a randomized, double-blind, placebo-controlled cross-over study. The study consisted of two 8-week treatment periods separated by 2 weeks of wash-out. The primary endpoint was the median value of the mean daily pain score during the last week of treatment while treated with 200 mg/d lamotrigine. Secondary endpoints were median pain scores while on lamotrigine 25 mg/d, 50 mg/d, and 100 mg/d; a global pain score; assessment of evoked pain; areas of spontaneous pain; and allodynia/dysesthesia.
RESULTS: Lamotrigine 200 mg/d reduced the median pain score to 5, compared to 7 during placebo (p = 0.01) in the intent-to-treat population of 27 patients. No significant effect was obtained at lower doses. Twelve patients (44%) responded to the treatment. There was a uniform tendency to reduction of all secondary outcome measures, but lamotrigine only had significant effects on some of the secondary outcome measures. Lamotrigine was well tolerated with few and transient side effects. Two mild rashes occurred during lamotrigine treatment, one causing withdrawal from study.
CONCLUSIONS: Oral lamotrigine 200 mg daily is a well tolerated and moderately effective treatment for central poststroke pain. Lamotrigine may be an alternative to tricyclic antidepressants in the treatment of CPSP.
This article has been cited by other articles:
|
|
 |
|
  R. H. Dworkin, J. Katz, and M. J. Gitlin Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology, December 29, 2005; 65(12_suppl_4): S7 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Irving Contemporary assessment and management of neuropathic pain Neurology, June 28, 2005; 64(12_suppl_3): S21 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Rubey Treatment of chronic pain in persons with dementia: An overview American Journal of Alzheimer's Disease and Other Dementias, January 1, 2005; 20(1): 12 - 20. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Lussier, A. G. Huskey, and R. K. Portenoy Adjuvant Analgesics in Cancer Pain Management Oncologist, September 1, 2004; 9(5): 571 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Young, L. Gyulai, B. H. Mulsant, A. Flint, J. L. Beyer, K. I. Shulman, and C. F. Reynolds III Pharmacotherapy of Bipolar Disorder in Old Age: Review and Recommendations Am J Geriatr Psychiatry, August 1, 2004; 12(4): 342 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B Svendsen, T. S Jensen, and F. W Bach Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial BMJ, July 31, 2004; 329(7460): 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pellock Understanding co-morbidities affecting children with epilepsy Neurology, March 9, 2004; 62(90052): S17 - 23. [Abstract] [Full Text]
|
|
|
|
|
|
B. D. Nicholson Evaluation and treatment of central pain syndromes Neurology, March 9, 2004; 62(90052): S30 - 36. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. H. Dworkin, M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, et al. Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations Arch Neurol, November 1, 2003; 60(11): 1524 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Simpson, J. C. McArthur, R. Olney, D. Clifford, Y. So, D. Ross, B. J. Baird, P. Barrett, A. E. Hammer, and the Lamotrigine HIV Neuropathy Study Team Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial Neurology, May 13, 2003; 60(9): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Cohen and S. Abdi Venous Malformations Associated with Central Pain: Report of a Case Anesth. Analg., November 1, 2002; 95(5): 1358 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-M. Backonja Use of anticonvulsants for treatment of neuropathic pain Neurology, September 10, 2002; 59(90052): S14 - 17. [Abstract] [Full Text]
|
|
|
|
|
|
T. S. Jensen and S. H. Sindrup Opioids: A way to control central pain? Neurology, February 26, 2002; 58(4): 517 - 518. [Full Text] [PDF]
|
|
|
|
|
|
N. Attal, F. Guirimand, L. Brasseur, V. Gaude, M. Chauvin, and D. Bouhassira Effects of IV morphine in central pain: A randomized placebo-controlled study Neurology, February 26, 2002; 58(4): 554 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Eisenberg, Y. Lurie, C. Braker, D. Daoud, and A. Ishay Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study Neurology, August 14, 2001; 57(3): 505 - 509. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
